



25th November, 2024

**Listing Department
National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G. Block,
Bandra- Kurla Complex,
Bandra East, Mumbai-400 051**

**Corporate Relationship Department
BSE Ltd.
1st Floor New Trading, Rotunda Building,
P J Towers, Dalal Street Fort,
Mumbai- 400 001**

Ref: Symbol- DHANUKA

Scrip Code: 507717

Sub: Intimation of the signing of Agreement by Dhanuka Agritech Limited (“Dhanuka”) with Bayer AG, Germany for the acquisition of active ingredients named “Iprovalicarb” and “Triadimenol”.

Ref: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To all stakeholders

Dhanuka Agritech Ltd. has signed an Agreement with Bayer AG, Germany for the acquisition of the crop protection active ingredients named “Iprovalicarb” and “Triadimenol” along with the trademark Melody for Iprovalicarb. This Agreement signed by Dhanuka is subject to completion of certain closing actions. This acquisition will help Dhanuka to expand its business in India and in overseas markets and with this Dhanuka will make its global presence.

The above intimation is in pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time.

Further, the detailed disclosure pursuant to the provisions of Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“LODR Regulations”) read with Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023, is enclosed as Annexure-A.

The aforementioned information shall also be available on Dhanuka's website www.dhanuka.com

For Dhanuka Agritech Limited

**Jitin Sadana
Company Secretary and Compliance Officer
FCS-7612**

Encl: a/a



Annexure A

S. No	Particulars	Disclosures
1.	Name of the Party with whom the agreement is entered	Bayer AG, incorporated in Germany
2.	Purpose of entering into the agreement	For the acquisition of the active ingredients named "Iprovalicarb" and "Triadimenol" from an overseas entity named Bayer AG
3.	Shareholding, if any, in the entity with whom the agreement is executed	NIL
4.	Significant terms of the agreement (in brief), special rights like right to appoint directors, first right to share subscription in case of issue of shares, right to restrict any change in capital structure etc.	Dhanuka will get the rights to sell these products in India and various countries outside India.
5.	Whether, the said parties are related to the promoter/promoter group/ group companies in any manner. If yes, nature of relationship	NO
6.	Whether the transaction would fall within related party transaction? If yes, whether the same is done at "arms' length"	NO
7.	In case of issuance of shares to the parties, details of issue price, class of shares issued	NIL
8.	Any other disclosures related to such agreements, viz. details of the nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc.	NIL
9.	In case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s): i. Name of the parties to the agreement ii. Nature of the agreement iii. Date of execution of the agreement iv. Details of the amendment and impact thereof or reasons of termination and impact thereof	NA